End-of-day quote
Other stock markets
|
||
- CAD | - |
02-12 | Acasti Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 | CI |
02-07 | Craig-Hallum Initiates Acasti Pharma With Buy Rating, $6 Price Target | MT |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 34.4M 25.26M |
---|---|---|---|---|---|
Net income 2024 * | -18M -13.22M | Net income 2025 * | -23M -16.89M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.89
x | P/E ratio 2025 * |
-2.43
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 83.98% |
Latest transcript on Acasti Pharma Inc
Managers | Title | Age | Since |
---|---|---|---|
Prashant Kohli
CEO | Chief Executive Officer | 52 | 21-07-31 |
Director of Finance/CFO | 52 | 01-04 | |
Carrie D'Andrea
CTO | Chief Tech/Sci/R&D Officer | 52 | 23-05-07 |
Members of the board | Title | Age | Since |
---|---|---|---|
A. Davis
BRD | Director/Board Member | 57 | 23-10-09 |
Director/Board Member | - | 23-10-09 | |
Santosh Kottayil
BRD | Director/Board Member | - | 23-10-09 |
1st Jan change | Capi. | |
---|---|---|
+32.09% | 693B | |
+29.39% | 584B | |
-1.34% | 372B | |
+20.34% | 332B | |
+7.39% | 294B | |
+14.25% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+8.49% | 168B |
- Stock Market
- Equities
- ACST Stock
- APO Stock